Oncolytics Biotech Inc T.ONC

asco abstract info

[itntdf]

Results:Forty-eight pts were enrolled between June 2020 and June 2022. Median age was 55.5 yrs, range 37-74. Forty pts (83%) had visceral disease. Six pts (12%) previously received everolimus, and 3 alpelisib. Thirteen pts (27%) received prior taxanes in the neo/adjuvant setting. Three pts who withdrew consent prior to starting therapy and 2 pts who discontinued treatment after week 1 were considered non-responders and were censored for PFS. The most common pelareorep-associated toxicities were fever, chills, and flu-like infusion reactions, which were occasionally severe enough to require hospitalization in 5 (15%) pts despite acetaminophen prophylaxis. Nine pts (33%) discontinued pelareorep and 6 (35%) discontinued avelumab due to toxicity. Pelareorep increased T-cell repertoire turnover, with identification and expansion of new and pre-existing T-cell clones by C2D1.Conclusions:The addition of pelareorep to PTX is an active regimen with a high 6-month PFS rate worthy of further study. One third of patients discontinued either pelareorep or avelumab due to toxicity, highlighting the need for attentive supportive care. Survival data is maturing. Clinical trial information: NCT04215146.

	Cohort 1 (n = 15)	Cohort 2 (n = 16)	Cohort 3 (n = 17)
ORR at 16 wks	3 (20%)	5 (31.3%)	3 (17.6%)
Disease Control at 16 wks (CR+PR+SD)	7 (46.7%)	10 (62.5%)	12 (70.6%)
Median PFS	6.4 months (95% CI: 2.0,-)	9.6 months (95% CI: 6.5,-)	7.5 months (95% CI: 3.8,-)
6-month PFS rate	62.5% (95% CI: 27.6, 84.2)	92.9% (95% CI: 59.1, 99.0)	73.2% (95% CI: 42.0, 89.4)

[westcoast1000]

itntdf Are those the results released previously with data from November 2022, or the latest data? Any guidance from readers as to interpretation? Thanks for any viewpoints here.

[itntdf]

only through june 2022 with comment "data still maturing".  hopefully monday will give us the newer data. could not access slides of abstract so don't know if there will be any newer or hints of new info at the oral presentation.

[Azzak34]

Up to date results today. KOL to discuss results on Monday. You post was for data cut off October 2022. 

[westcoast1000]

Thanks azzak.

[itntdf]

wonder if they had up to date results today why the oral presentation in abstract 1012 which was what was presented and discussed today didn't have up to date results.  what was posted at 1:15 was from asco's site.   agree it was data from cut off last year but that is what was posted and released. if monday doesn't have updated data, can't imagine the stock price

[Lesalpes29]

Matured datas are suppose to be released, no? Waiting for monday morning. GL

[Azzak34]

They tweeted "join us for exciting news on the results", check stockwits. They wouldn't say that if they were merely discussing data we already have. Also the KOL panel is insane, the new data must be great! 

[Snowdrift]

Azzak, that's not quite what was tweeted. The exact quote was "Join us Monday June 5 at 8 am ET for a discussion of the exciting BreastCancer data from this study." So they're not saying they have news on the results.  They're just asking people to watch the KOL discussion about the results. Regards, Snowdrift

[Azzak34]

Cant argue on the wording verbatim however my point is the new ASCO data is updated to May of this year, they've stated this numerous times. The KOL is to discuss the matured data, not last weeks release.